McKesson Corporation $MCK Shares Bought by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC boosted its stake in shares of McKesson Corporation (NYSE:MCK) by 5.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 23,327 shares of the company’s stock after purchasing an additional 1,169 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in McKesson were worth $19,135,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MCK. Cullen Investment Group LTD. grew its position in shares of McKesson by 550.4% during the 4th quarter. Cullen Investment Group LTD. now owns 4,670 shares of the company’s stock valued at $3,811,000 after acquiring an additional 3,952 shares during the period. Pensionfund Sabic acquired a new stake in shares of McKesson during the 4th quarter valued at about $1,887,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in shares of McKesson by 18.8% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 10,009 shares of the company’s stock valued at $7,732,000 after acquiring an additional 1,585 shares during the period. PNC Financial Services Group Inc. grew its position in shares of McKesson by 24.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 242,256 shares of the company’s stock valued at $187,152,000 after acquiring an additional 47,352 shares during the period. Finally, Achmea Investment Management B.V. grew its position in shares of McKesson by 7.5% during the 3rd quarter. Achmea Investment Management B.V. now owns 61,287 shares of the company’s stock valued at $47,347,000 after acquiring an additional 4,260 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MCK. Wells Fargo & Company dropped their target price on McKesson from $925.00 to $812.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings cut McKesson from a “buy (b+)” rating to a “buy (b)” rating in a research report on Monday, May 18th. Bank of America dropped their target price on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Leerink Partners restated an “outperform” rating and set a $1,085.00 target price on shares of McKesson in a research report on Thursday, March 5th. Finally, William Blair began coverage on McKesson in a research report on Tuesday, April 28th. They set an “outperform” rating on the stock. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, McKesson has an average rating of “Moderate Buy” and a consensus target price of $960.53.

McKesson Trading Down 0.0%

MCK stock opened at $783.88 on Monday. The company has a market cap of $94.22 billion, a price-to-earnings ratio of 20.38, a PEG ratio of 1.29 and a beta of 0.31. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00. The firm has a 50-day moving average of $798.10 and a two-hundred day moving average of $846.19.

McKesson (NYSE:MCK) last released its quarterly earnings data on Thursday, May 7th. The company reported $11.69 EPS for the quarter, beating analysts’ consensus estimates of $11.56 by $0.13. The company had revenue of $96.30 billion during the quarter, compared to the consensus estimate of $101.35 billion. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. McKesson’s quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $10.12 EPS. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. As a group, equities analysts forecast that McKesson Corporation will post 44.28 earnings per share for the current year.

McKesson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s payout ratio is presently 8.53%.

Insider Activity

In other news, EVP Thomas L. Rodgers sold 699 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $735.27, for a total value of $513,953.73. Following the transaction, the executive vice president owned 2,268 shares of the company’s stock, valued at $1,667,592.36. This represents a 23.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $764.00, for a total value of $101,612.00. Following the transaction, the chief accounting officer owned 632 shares of the company’s stock, valued at approximately $482,848. This represents a 17.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,822 shares of company stock worth $8,986,212 in the last 90 days. 0.08% of the stock is owned by corporate insiders.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.